Latest Leadership News

Osmond Resources has reported compelling high-grade assay results from its Orión EU Critical Minerals Project in Spain, confirming the potential for a large-scale deposit of titanium, zircon, and rare earth elements. These findings reinforce the project's strategic importance amid growing EU demand for critical minerals.

Beamtree Holdings Limited reported a 2% rise in total revenue and a reduced net loss in the first half of FY26, driven by a 10% increase in recurring revenue. The company is advancing AI-powered healthcare products and has initiated a strategic review to unlock shareholder value.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.

Ventia Services Group Limited reported a 23.6% increase in profit after tax for FY25 to $272.2 million, alongside record contract wins and a strong sustainability agenda. The company declared a 12.54 cents per share final dividend, underscoring its commitment to shareholder returns and operational excellence.

Australian Vintage reports steady first-half sales and outlines a robust strategy focused on innovation, portfolio diversification, and global expansion to meet full-year growth targets.

Transurban Group posted robust half-year results for December 2025, with revenue climbing 8.1% and profit rebounding to $343 million. The company also declared a 34-cent interim distribution, underpinned by strong cash flow and key project milestones.

InvestSMART Group Ltd reports a solid half-year performance with funds under management reaching $750 million and a growing subscriber base, while outlining plans to enhance its digital wealth platform with AI and new services.

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.